| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | The human colorectal carcinoma cell line HT29 was used as the immunogen for the was used as the immunogen for the Cytokeratin CAM5.2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target |
Overview
Cytokeratin CAM5.2 Antibody / Cytokeratin 7/8 is an antibody targeting Cytokeratin. Host: Mouse. Monoclonal. Clone: CAM5.2. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: Cytokeratin.
- Immunogen: The human colorectal carcinoma cell line HT29 was used as the immunogen for the was used as the immunogen for the Cytok….
- Species reactivity: Human.
- Localization: Cytoplasm.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Cytokeratin CAM5.2 antibody has a primary reactivity with human keratin proteins that correspond to Moll’s peptides #7 and #8, MW 48 and 52 kDa, respectively.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
